Prognostic value of heart rate variability during long-term follow-up in patients with mild to moderate heart failure by Brouwer, J. (Jan) et al.
JACC Vol. 28, No. 5 1183 
November 1, 1996:1183-9 
Prognostic Value of Heart Rate Variability During Long-Term 
Follow-Up in Patients With Mild to Moderate Heart Failure 
JAN BROUWER,  MD, D IRK  J. VAN VELDHUISEN,  MD, FACC, AR IE  J. MAN IN 'T VELD,  MD,* 
JAAP HAAKSMA,  BSc, W. ARNOLD DIJK, PHD, KLAAS R. VISSER, PaD, 
FRANS BOOMSMA,  PHD,* PETER H. J. M. DUNSELMAN,  MD, t  K.I. LIE, MD, FOR THE DUTCH 
IBOPAMINE MULTICENTER TR1AL STUDY GROUP:~ 
Groningen, Rotterdam and Breda, The Netherlands 
Objectives. We sought to assess the prognostic value of heart 
rate variability measures, including Poincar~ plots, in patients 
with mild to moderate chronic heart failure. 
Background. Mortality is high in patients with heart failure, 
and many of them die suddenly. However, identification of high 
risk patients, particularly those with an increased risk for sudden 
death, has remained difficult. 
Methods. We studied 95 patients with heart failure (mean 
[_+SD] age 60 -+ 8 years, left ventricular ejection fraction 0.29 -+ 
0.09, New York Heart Association functional class II [81%] and 
III [19%]) during up to 4 years of follow-up. Heart rate variability 
measures and Poincar~ plots were obtained from 24-h Holter 
recordings. 
Results. During follow-up, 17 (18%) of the 95 patients died. In 
15 patients, death was cardiac related (11 patients experienced 
sudden death). None of the conventional time and frequency 
domain measures of heart rate variability were related to survival. 
In contrast, abnormal Poincar~ plots identified a significantly 
higher risk for all-cause cardiac death (Cox proportional hazards 
ratio 5.7, 95% confidence interval [CI] 1.6 to 20.6, univariate 
analysis) and for sudden cardiac death (hazards ratio 6.8, 95% CI 
1.5 to 31.4) compared with those with normal Poincar6 plots. 
Patients with abnormal Poincar~ plots were shown to have a lower 
left ventricular ejection fraction (0.26 -+ 0.10 vs. 0.31 _+ 0.08, p < 
0.05) and higher plasma norepinephrine concentrations (506 + 
207 pg/ml vs. 411 -+ 175 pg/mi, p < 0.05). In multivariate analysis, 
abnormal Poincar6 plots still had independent prognostic value, 
both for all.cause cardiac mortality and for sudden cardiac death 
(hazards ratio 5.3, 95% CI 1.2 to 17.1, hazards ratio 4.5, 95% CI 
1.0 to 27.5, respectively. 
Conclusions. Heart rate variability analysis, as assessed by 
Poincar~ plots, has independent prognostic value in patients with 
mild to moderate chronic heart failure and identifies an increased 
risk for all-cause and sudden cardiac death in these patients. 
(J Am Coil Cardiol 1996;28:1183-9) 
Mortality is high in patients with chronic congestive heart 
failure, and death often occurs suddenly (1). Although a 
number of measures, uch as left ventricular ejection fraction 
(2,3), plasma norepinephrine (4,5), peak oxygen consumption 
(3) and ventricular arrhythmias (2), have been associated with 
all-cause mortality in heart failure, it has remained ifficult to 
identify heart failure patients at an increased risk of sudden 
cardiac death. Recent studies suggest hat death in severe 
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heart failure is often due to progressive pump failure, whereas 
in less advanced isease, a relatively higher proportion of 
deaths occur suddenly (6,7). Because these patients usually 
have only mild symptoms, udden death is particularly devas- 
tating in this group and identification of such patients is 
therefore important. 
In patients with chronic heart failure, abnormal autonomic 
control has been recognized as a potential explanation for the 
observed increased mortality (8). Analysis of heart rate vari- 
ability is a noninvasive means of studying autonomic ontrol of 
the heart (9-11). Several studies have shown disturbed heart 
rate variability in patients with heart failure, and the degree of 
impairment of heart rate variability appears to be related to 
the severity of the disease (12-16). It has recently been 
suggested that Poincar6 plots, which represent beat to beat 
variations in heart rate, may provide even better insight into 
the abnormal autonomic ontrol of the heart (17-20). In 
patients with early-stage heart failure, the predictive value for 
sudden death of neither conventional heart rate variability 
measures nor Poincar6 plots has been established. 
The purpose of the present study was to examine the 
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Table 1. Definition of Heart Rate Variability Measures 
Variable Definition 
Time domain 
Mean NN (ms) 
SDNN (ms) 
SDANN (ms) 
pNN50 ((~) 
Frequency domain 
Total power (ms-') 
Ve~, low frequency power (ms:) 
Low frequenq, power (ms:) 
High frequency power (ms~') 
Mean of all normal to normal RR intervals during 24 h 
Standard eviation of all normal to normal RR intervals during 24 h 
Standard eviation of all 288 averages during 24 h 
of normal to normal RR intervals in 5-min segments 
Percent of differences between successive normal RR intervals >50 ms 
Energy in power spectrum between 0.0033 and 0.40 Hz 
Energy. in power spectrum between 0.0033 and 0.04 Hz 
Energy. in power spectrum between 0.04 and 0.15 Hz 
Ener~' in power spectrum between 0.15 and 0.40 Hz 
prognostic value of heart rate variability measures, including 
Poincar6 plots, in patients with mild to moderate chronic heart 
failure during 2 to 4 years of follow-up. The study patients had 
participated in a recently published multicenter heart failure 
study in the Netherlands (21). 
Methods  
Study group. Patients aged 18 to 75 years who had func- 
tional class II or III chronic heart failure and were clinically 
stable for at least 2 weeks were eligible for the study, as 
previously described (21). Chronic heart failure was character- 
ized by clinical signs and symptoms and a radionuclide l ft 
ventricular ejection fraction -<0.45 obtained within the previ- 
ous 2 months. Patients were excluded from participation if
heart failure was due to hemodynamically significant valvular 
or congenital heart disease, active myocarditis, thyroid disease 
or hypertrophic obstructive cardiomyopathy. Further exclusion 
criteria were exercise-limiting angina pectoris, myocardial in- 
farction or a major surgical procedure within the previous 2 
months, severe hypertension, atrial fibrillation or flutter, pace- 
maker therapy, ahistory of sustained ventricular tachyarrhyth- 
mias, chronic obstructive lung disease, severe hepatic or renal 
disease and insulin-dependent diabetes mellitus. 
Baseline measures. At the end of a placebo treatment 
period of 7 to 10 days, a 24-h ambulatory Holter recording was 
obtained for analysis of heart rate variability and arrhythmias, 
and venous blood was collected for determination f plasma 
neurohormonal concentrations. At baseline, up to 80 rag/day 
of furosemide was allowed as background therapy, as well as 
short-acting nitrates. Triamterene was also permitted to con- 
trol serum potassium levels. Other drugs for treatment ofheart 
failure, including angiotensin-converting enzyme inhibitors, 
alpha- or beta-adrenergic blocking agents and calcium antag- 
onists, were not allowed. The protocol was approved by the 
Ethics Committee of each participating center and was con- 
ducted in accordance with the revised Declaration of Helsinki. 
Before entry, into the study, all patients gave written informed 
consent. 
Follow-up. The patients were followed for at least 2 years 
after the baseline measures. Deaths were classified as sudden 
cardiac death, nonsudden cardiac death or noncardiac death 
by physicians who had no knowledge of the heart rate variabil- 
ity analyses. Sudden cardiac death was defined using standard 
criteria (22)--i.e., as unexpected death that occurred within 1 h 
of new or more serious symptoms, or during sleep or while 
unobserved, in the absence of increasing angina pectoris or 
progressive heart failure. During the first 6 months, patients 
were randomly allocated to double-blind study medication 
(i.e., digoxin, ibopamine [an orally active dopamine agonist] or 
placebo) (21). Thereafter, patients were treated by their 
attending physician and received standard treatment for 
chronic heart failure. Drug use was scored at the last available 
date during follow-up. 
Neurofiormonal levels. Venous blood for the determina- 
tion of plasma neurohormonal levels was drawn after 30 min of 
supine rest, in the morning hours between 8 AM and 11 AM. 
Plasma norepinephrine, aldosterone and renin concentrations 
were analyzed in a central core laboratory. Plasma norepineph- 
fine (23) and plasma renin (24) concentrations were measured 
as described previously; plasma ldosterone concentration was 
measured using a commercially available radioimmunoassay kit 
(Aldokit, Labservice Benelux, Apeldoorn, The Netherlands). 
Analysis of heart rate variability. The 24-h ambulatory 
Holter recordings were analyzed on a Marquette 8000 Holter 
system (Marquette Electronics, Inc.) by an experienced analyst 
(J.H.) and supervised by one physician (J.B.). All heart rate 
variability analyses were performed without knowledge of the 
clinical characteristics of the patients. Recordings with more 
than 15% noise or ectopic beats during 24 h were excluded 
from the heart rate variability analysis. For the calculation of 
heart rate variability, the data file of RR intervals was trans- 
ferred to a personal computer. From the time series of RR 
intervals, time and frequency domain variables were calculated 
(Table 1). The variables were computed over consecutive 
5-min segments. Segments with more than 15% noise or 
ectopic beats were excluded from the analysis. Before calcula- 
tion of the frequency domain variables in the other segments, 
episodes with noise and ectopic beats were substituted by 
holding the previous normal to normal interval constant 
throughout the entire period. Spectral analysis was performed 
using the discrete Fourier transform algorithm (25-28). Low 
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Figure l. Examples of Poincar6 plots. Ex- 
ample of a normal Poincar6 plot is shown 
at the upper left; the other three plots are 
abnormal. Upper left plot is from a 50-year 
old man who was alive after 2.9 years of 
follow-up. Lower left plot ("narrow" pat- 
tern) is from a 55-year old man who died 
suddenly after 132 days of follow-up. Up- 
per fight plot (also narrow pattern) is from 
a 68-year old man who died suddenly after 
67 days of follow-up. Lower right plot 
("complex" pattern) is from a 55-year old 
man who died suddenly after 3.4 years of 
follow-up. The left ventricular ejection 
fraction of these patients was 0.25, 0.18, 
0.21 and 0.44, respectively. Their plasma 
norepinephrine concentration was 533, 
329, 387 and 427 pg/ml, respectively. 
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and high frequency power was also expressed in normalized 
units, analogous to calculations used in autoregressive models. 
Furthermore, the ratio between low and high frequency power, 
which is considered a measure of sympathovagal balance, was 
calculated (11,29). 
Poincar~ plots. These plots were constructed by plotting 
each normal to normal RR interval against its subsequent 
normal to normal RR interval. RR intervals related to ectopic 
beats or to noise were excluded from the analysis. Poincar6 
plots were classified as described previously by Woo et al. 
(18,19). They were considered to be normal when increasing 
RR interval dispersion was observed with increasing RR 
intervals (i.e., lower heart rate) (Fig. 1). Two types of abnormal 
Poincar6 plots are generally recognized: "narrow" patterns, 
with little or no increase in RR interval dispersion at longer 
RR intervals, and "complex" patterns, with clusters of RR 
intervals aligning a small core area of RR intervals (Fig. 1). 
Statistical analysis. Data are presented as the mean 
value _+ SD, unless otherwise indicated. For comparison ofthe 
baseline data, the Student t test, Wilcoxon rank-sum test (for 
non-normally distributed variables) and the Fisher exact test 
(for categoric variables) were used. Mean values of heart rate 
variability measures were calculated for the complete 24-h 
period. Survival analysis was performed using a Cox propor- 
tional hazards model (EGRET package, version 0.26.6). When 
estimating the association of continuous variables with mortal- 
ity, the patients were dichotomized by the median value of the 
examined variable. For the standard eviation of all normal to 
normal RR intervals during 24 h, we also evaluated the cutoff 
value of 50 ms, as defined by Kleiger et al. (30) in their study 
in postinfarction patients. Kaplan-Meier survival curves were 
calculated for graphic display of survival. For all comparisons, 
p < 0.05 was considered statistically significant. 
Resu l ts  
Baseline measures. Holter recordings for heart rate vari- 
ability analysis were available in 95 of the 161 patients in the 
original Dutch Ibopamine Multicenter Trial (DIMT) study 
group (21). Their mean (_+SD) age was 60 _+ 8 years and left 
ventricular ejection fraction 0.29 _+ 0.09. Of all the patients, 82 
(86%) were men and 13 (14%) were women; 78 patients (82%) 
were in functional c ass II and 17 (18%) were in class III. Heart 
failure was due to coronary artery disease in 71 patients and 
due to idiopathic dilated cardiomyopathy in 24 patients. At 
baseline, 53 patients were taking furosemide, at an average 
dose of 25 _+ 17 rag. 
Conventional analysis of heart rate variability could be 
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Table 2. Characteristics at Baseline in Relation to Survival (n -- 95) 
Survivors Nonsurvivors p 
(n = 78) (n 17) Value 
Age (yr) 59 _+ 7 61 + 9 NS 
Male/female (%) 85/15 94/6 NS 
LVEF 0.30 _+ 0.09 0.23 -+ 0.10 0.009 
NYHA functional class II/II1 (%) 85/15 71/29 NS 
Ischemic HF/idiopathic HF (%) 78/21 65,/35 NS 
Hemodynamic data 
HR (beats/vain) 78 _+ 12 86 - 15 0.027 
SBP (ram Hg) 131 _+ 17 13I _+ 19 NS 
DBP (ram Hg) 83 _+ 9 83 -+ 7 NS 
Plasma neurohormones 
Norepinephrine (pg/ml) 421 (119-883) 507 (329-1,112) 0.014 
Aldosterone (pg/ml) 87 (8-498) 128 (16-373) NS 
Renin (gU/ml) 19 (3-82) 22 (7-58) NS 
Arrhythmias on 24-h Holter ECG 
Ventricular premature beats (h 1) 12 (1-780) 26 (1-549) 0.048 
Ventricular tachycardia (%) 36 65 0.028 
Drug use (%)* 
Diuretics 66 93 0.034 
Digoxin 40 60 NS 
ACE 45 47 NS 
Ibopamine 211 27 NS 
Calcium antagonists 9 27 NS 
Other vasodilating drugs 20 20 NS 
Beta-blockers 21 14 NS 
Antiarrhythmic drugs 13 27 NS 
Anticoagulants 43 47 NS 
Antiplatelet agents 29 40 NS 
*Drug use as scored at last follow-up visit. Data presented are mean value _+ SD, median (range) or percent of 
patients. ACE = angiotensin-converting enzyme; DBP = diastolic blood pressure; ECG = electrocardiogram; HF = 
heart failure: LVEF = left ventricular ejection fraction; NYHA - New York Heart Association; SBP - systolic blood 
pressure. 
performed in 87 of the 95 patients; in 8 patients ectopic beats 
or noise precluded a reliable analysis. In 6 of these 8 patients, 
frequent ventricular premature beats precluded heart rate 
variability analysis. Poincar6 plots were available in all 95 
patients. They were classified as normal in 57 patients (60%) 
and as abnormal in the other 38 (40%). Of these 38 abnormal 
Poincar6 plots, 32 showed a narrow pattern and 6 a complex 
pattern. 
Between left ventricular ejection fraction and the heart rate 
variability measures, only moderate but statistically significant 
correlations were observed (r = 0.23 to 0.36, p < 0.05 to 0.01). 
Furthermore, there were negative correlations between plasma 
norepinephrine concentration a d heart rate variability mea- 
sures (r = -0.30 to -0.41, p < 0.05 to 0.001). Patients with 
abnormal Poincar6 plots had a significantly ower left ventric- 
ular ejection fraction (0.26 _+ 0.10 vs. 0.31 _+ 0.08, p < 0.05) 
and a higher plasma norepinephrine concentration (506 + 207 
pg/ml vs. 411 _+ 175 pg/ml, p < 0.05). 
Follow-up. The records for all 95 patients were available 
for follow-up. During follow-up, 17 patients died. In two 
patients, the cause of death was noncardiac (one bronchial 
carcinoma, one cerebrovascular ccident). Fifteen patients 
died from cardiac reasons; there were 11 sudden deaths and 4 
other cardiac deaths (3 progressive heart failure, 1 fatal 
myocardial infarction). The duration of follow-up ranged from 
2.0 to 3.9 years for surviving patients (mean 2.6) and from 8 
days to 3.4 years for the patients who died (mean 1.5). The 
baseline characteristics for survivors and nonsurvivors are 
listed in Table 2. Left ventricular ejection fraction was signif- 
icantly lower in the group of nonsurvivors. Heart rate, plasma 
norepinephrine concentration a d number of ventricular pre- 
mature heartbeats were all higher and the presence of ventric- 
ular tachycardias was more common in the group of nonsur- 
vivors. Furthermore, patients who died were using diuretics 
significantly more often than those who survived. There were 
no other differences in drug use between the two groups. Also, 
biochemical measures ( erum sodium and potassium not tab- 
ulated) showed no significant differences between survivors 
and nonsurvivors. 
Survival analysis. In Table 3, the univariate r lative risk of 
mortality in relation to clinical variables is listed. In patients 
with a low left ventricular ejection fraction, the relative risk of 
cardiac death and sudden death was significantly higher in 
patients with relatively preserved left ventricular ejection frac- 
tion (Cox proportional hazards ratio 4.3 and 4.9, respectively). 
Ventricular arrhythmias were related to all-cause cardiac 
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Table 3. All-Cause, Cardiac and Sudden Death in Relation to Clinical and Heart Rate Variabiliw 
Measures--Univariate CoxProportional Hazards Survival Analysis (n = 95) 
Cardiac Death Sudden Death 
Variable (cutoff value) RR 95% CI RR 95% CI 
Clinical variables 
LVEF (<0.30) 4.3* 1.2-15.3 4.9* 1.0-22.5 
Plasma norepinephrine (>435 pg/ml) 2.1 0.7-6.3 1.9 0.6-6.4 
Ventricular premature beats (>20/h) 4.0* 1.1-14.3 4.3 0.9-20.4 
Ventricular tachycardia (present) 3.0* 1.0-8.9 2.7 0.8-9.1 
Time domain measures of heart rate variability 
Mean NN interval (<750 ms) 1.1 0.4-2.9 1.1 0.3-3.6 
SDNN (<110 ms) 1.2 0.4-3.5 2.0 0.5-8.0 
SDNN (<50 ms)t 3.6 0.5-27.8 5.4 0.7-43.4 
SDANN (<100 ms) 1.2 0.4-3.5 1.3 0.3-4.7 
pNN50 (<2.0%) 2.2 0.8-6.5 3.0 0.8-11.2 
Frequency domain measures of heart rate variability 
Total power (<2,500 ms 2) 1.7 0.6- 4.8 2.0 0.6 - 6.8 
Very low frequency power (< 1,500 ms 2) 1.3 0.4-4.4 1.3 0.4-4.4 
Low frequency power (<300 ms z) 1.6 0.6-4.4 1.8 0.5-6.2 
High frequency power (<100 ms z) 1.7 0.6-4.6 1.3 0.4-4.3 
Poincar6 plot (abnormal) 5.7:~ 1.6-20.6 6.8* 1.5-31.4 
*p < 0.05. -iCutoff value as used by Kleiger et al. (30). For all other variables, the median value was used as cutoff 
value. Ventricular tachycardia was classified as present or absent (n = 39 and n = 56, respectively), and Poincar6 plots 
as abnormal or normal (n = 38 and n = 57, respectively). ~:p < 0.01. CI = confidence interval; RR = relative risk (hazards 
ratio from the Cox proportional hazards analysis); other abbreviations a  in Tables 1 and 2. 
death but not to sudden death. Other clinical variables, 
including the neurohormones measured, only revealed trends 
for an association with increased mortality, which reached no 
statistical significance (Table 3). The frequency domain mea- 
sures of heart rate variability, expressed in normalized units, 
and the ratio of low-to-high frequency power also showed only 
nonsignificant trends for a relation with increased mortality 
(not tabulated). 
Poincar6 plots were the only heart rate variability measure 
that identified an increased risk for mortality, both for all- 
cause cardiac death and sudden death (Table 3, Fig. 2). Of the 
38 patients with abnormal Poincar6 plots, 12 (32%) died of a 
Figure 2. Kaplan-Meier survival curves for cardiac death in patients 
with normal versus abnormal Poincar6 plots (Cox proportional hazards 
ratio 5.7, 95% CI 1.6 to 20.6, p < 0.05). 
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cardiac ause, and 9 of these patients died suddenly. Of the 57 
patients with normal Poincar6 plots, 3 (5%) died during 
follow-up, and 2 of these deaths were sudden. 
When dividing all patients with abnormal Poincar6 plots 
into narrow (n = 32) and complex (n = 6), the hazards ratio 
for cardiac death was 5.2 in patients with a narrow Poincar6 
plot and 8.8 in patients with a complex Poincar6 plot (95% 
confidence interval [CI] 1.4 to 19.2 and 1.7 to 44.7, respective- 
ly). The hazards ratio for sudden cardiac death was 5.4 in 
patients with a narrow Poincar6 plot and 13.5 in patients with 
a complex Poincar6 plot (95% CI 1.1 to 27.0 and 2.2 to 82.9, 
respectively). 
In multivariate survival analysis, abnormal Poincar6 plots 
were found to have prognostic value independent of left 
ventricular ejection fraction, plasma norepinephrine, v ntricu- 
lar premature beats and presence of ventricular tachycardia 
(Table 4). The hazards ratio, based on abnormal Poincar6 
plots, for cardiac death and sudden death was 4.5 and 5.3, 
respectively. 
Discuss ion  
The main finding of the present study is that in the early 
stages of heart failure, heart rate variability, as assessed by 
Poincar6 plots, has prognostic value not only for the identifi- 
cation of patients at increased risk for all-cause cardiac mor- 
tality, but, more importantly, also for sudden cardiac death. 
Although the presence of an abnormal Poincar6 plot is asso- 
ciated with a lower left ventricular ejection fraction and a 
higher plasma norepinephrine concentration, it was also found 
to have independent prognostic value when using multivariate 
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Table 4. All-Cause, Cardiac and Sudden Death in Relation to Clinical and Heart Rate Variabili~ 
Measures--Multivariate CoxProportional Hazards Survival Analysis (n = 95) 
Cardiac Death Sudden Death 
Variable (cutoff value) RR 95% CI RR 95% CI 
LVEF (<0.30) 
Plasma norepinephrine (>45111 pg/ml) 
Ventricular premature beats (>20/h) 
Ventricular tachycardia (present) 
Poincar6 plot (abnormal) 
3.7 0.7-18.0 6.2 0.%53.5 
1.1 0.3-3.4 1.3 0.2-7.4 
3.4 0.9-12.9 4.0 0.8-19.7 
1.6 0.5-5.7 1.4 0.3-5.8 
4.5* 1.2-17.1 5.3* 1.0-27.5 
*p < 0.05. The median value of the variables was used as the cutoff value. Ventricular tachycardia was classified as 
present or absent (n 39 and n 56, respectively), and Poincard plots as abnormal or normal (n - 38 and n - 57, 
respectively). Abbreviations as in Tables 2 and 3. 
analysis. The predictive value of an abnormal Poincar6 plot 
therefore seems to be unrelated to other, well known risk 
factors in patients with heart failure (1-7). 
A number of variables have been associated with all-cause 
cardiac mortality in patients with chronic heart failure (1-7), 
but attempts to identify risk factors for sudden death have been 
disappointing so far. Recently, increased QT dispersion was 
found to be associated with an increased risk of sudden death 
in chronic heart failure (31). Furthermore, it has been sug- 
gested that relatively fast and long runs of ventricular tachy- 
cardia might also be related to sudden death (32). Plasma 
norepinephrine concentration has overall prognostic value in 
patients with heart failure, but it has not been shown to be 
related to an increased risk for sudden death (1,4,6,33). In the 
present study, left ventricular ejection fraction and ventricular 
arrhythmias were also related to cardiac mortality in univariate 
analysis, but only Poincar6 plots remained associated with both 
all-cause cardiac death and sudden cardiac death in the 
multivariate analysis. The prognostic value of a single measure 
of plasma norepinephrine concentration was less powerful 
than that of an abnormal Poincar6 plot. This finding may be 
explained by the fact that whereas Poincar6 plots reflect 
autonomic ontrol during 24 h, plasma norepinephrine is only 
an instantaneous a sessment of sympathetic activity. 
In patients with advanced heart failure, Woo et al. (20) 
reported that complex Poincar6 plots are associated with a 
higher risk of sudden death when compared with a narrow 
Poincard plot (20). In their study, patients with more severe 
heart failure were examined, and all patients were found to 
have abnormal Poincard plots. Our data indicate a lower 
incidence (45%) of abnormal Poincar6 plots in patients in the 
early stages of heart failure. When these patients are further 
divided, mortality appears to be higher in patients with a 
complex Poincar6 plot as compared with those with a narrow 
Poincar6 plot. Although the number of patients in these 
subgroups is small, it may therefore be hypothesized that 
complex Poincar6 plots reflect a more severe disturbance of 
the autonomic ontrol of the heart, which is apparently more 
often found in patients with severe heart failure (17). 
Study limitations. In our study, the conventional time and 
frequency domain measures of heart rate variability did not 
have significant prognostic value. However, in postmyocardial 
infarction patients (30), and also in patients with severe heart 
failure (34), several heart rate variability measures were re- 
ported to have significant value in assessing prognosis. The low 
prognostic value of conventional heart rate variability mea- 
sures in our study may be explained in part by the relative low 
mortality in this patient group with mild heart failure. Further- 
more, frequency domain measures of heart rate variability 
cannot always be calculated reliably in patients with heart 
failure because the incidence of ventricular premature com- 
plexes may be high. In our study, a reliable heart rate variabil- 
ity analysis could not be performed in eight patients (8%) for 
this reason. These patients with frequent premature ventricu- 
lar complexes, however, were also at a higher risk of mortality 
(Table 3). Finally, it was already pointed out by Woo et al. (19) 
that complex Poincar6 plots, which are apparently more often 
observed in patients with severe heart failure, are associated 
with increased beat to beat variability, which hampers recog- 
nition of patients at a higher risk using conventional measures 
of heart rate variability,. 
A further limitation of our study is that patients were not 
randomized by use of drugs during follow-up. Also, during the 
first 6 months of the study, patients received ifferent study 
medications (digoxin, ibopamine or placebo). After the first 6 
months of the study, the addition of other drugs by the treating 
physician may have influenced mortality during follow-up. 
However, baseline measures were performed using equal 
conditions for all patients. Furthermore, the use of drugs, 
except for diuretics, during follow-up was equal in survivors 
and nonsurvivors. We therefore believe that these effects are 
limited. It should also be realized that at the time this study 
was initiated, angiotensin-converting enzyme inhibition had 
not yet become standard treatment in patients with heart 
failure. Therefore, only 46% of the patients received treatment 
with an angiotensin-converting e zyme inhibitor during follow- 
up. 
Clinical implications. Our data indicate that in the early 
stages of heart failure, heart rate variability, as assessed by 
Poincar6 plots, has independent prognostic value. It may 
therefore provide a noninvasive clinical guide to prognosis in 
chronic heart failure and possibly in other cardiac disorders. 
Poincar6 plots provide information on autonomic ontrol of 
the heart, which is less readily recognized by other techniques. 
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Autonomic imbalance has been recognized to evolve early in 
the development of heart failure and probably plays a major 
role in progression of the disease (35). This rather unknown 
technique of constructing Poincar6 plots can be performed 
easily in patients with heart failure also. Further improvement 
may, however, be achieved by better quantification of the 
abnormalities in heart rate fluctuations that are observed in 
patients with chronic heart failure. In addition, our findings 
were obtained in a relatively small patient group. Therefore, 
our results need confirmation in larger patient groups to 
reliably establish the predictive value of an abnormal Poincar6 
plot in clinical practice. 
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